Drug Topics
APRIL 17, 2024
The ongoing opioid crisis in the United States shows no signs of slowing down. As trusted community health care professionals, pharmacists must play a key role in fighting it.
Pharmacy Times
APRIL 17, 2024
If approved, the test could provide more timely and accurate diagnosis, hopefully mitigating the impact of Alzheimer disease (AD) on individuals and the community.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Topics
APRIL 17, 2024
Researchers were unable to find a significant benefit for patients for the majority of cancer medications given accelerated FDA approval.
STAT
APRIL 17, 2024
Eli Lilly reported positive results for its obesity drug Zepbound in obstructive sleep apnea, giving the medication a new edge in the highly competitive obesity market. The results also pave the way for Zepbound to potentially become the first approved treatment for obstructive sleep apnea, or OSA, a common disorder characterized by breathing interruptions during sleep.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Drug Topics
APRIL 17, 2024
With an unprecedented number of Americans in need of mental health care, what role should pharmacists play when it comes to screenings?
STAT
APRIL 17, 2024
The fight against malaria is a test of human intelligence against mosquitoes — and so far, our minuscule winged enemy is winning. But new results shared this week show substantial improvements in one of the most important tools we have to prevent the life-threatening disease: bed nets. Results shared this week by the New Nets Project, an initiative funded by Unitaid and the Global Fund, highlighted a pair of second-generation bed nets tested in endemic areas between 2019 and 2022.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
STAT
APRIL 17, 2024
A new analysis of health inequities in the United States shows that every state has deep racial and ethnic disparities in the performance of their health care systems. The report released Thursday by the Commonwealth Fund analyzed 25 indicators that track health outcomes, health care access, and quality of care provided for five racial and ethnic groups.
Fierce Pharma
APRIL 17, 2024
One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis (MS) drug Ocrevus ahead of an FDA decision, the Swiss pharma said. | One-year data continued to support a more convenient, injectable version of Roche’s blockbuster multiple sclerosis drug Ocrevus ahead of an FDA decision, the Swiss pharma said.
STAT
APRIL 17, 2024
When my son Conall took his life at age 17, it was devastating to me and our entire family. Conall was a caring, empathetic, and bright young man, but he had also struggled for many years with anxiety and depression. Like many kids his age, much of his life revolved around social media. While I understand that suicide is complex, with many different factors contributing to someone’s risk for it, I know that social media intensified and fueled Conall’s insecurities and ultimately ha
Fierce Healthcare
APRIL 17, 2024
Though physicians are quickly growing more comfortable with generative AI, the vast majority expect models to be transparent and trained on credible information, a new
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Drug Topics
APRIL 17, 2024
Overall, older adults with diabetes faced a 53% higher risk of developing at least 1 functional limitation during the pandemic compared to older adults without diabetes.
STAT
APRIL 17, 2024
Federal rules forcing hospitals and insurers to post rates for medical procedures have taken effect, but the data’s so messy that a crop of new startups is rushing in to make a business out of parsing it for whoever is willing to pay. Silicon Valley venture funds Andreessen Horowitz and Yosemite, the cancer-focused fund launched by Steve Jobs’ son Reed Jobs , are backing the small but growing group of companies eager to sift through complex pricing data to help patients and employe
Pharmacy Times
APRIL 17, 2024
The product is currently being investigated alongside TLX101 in the IPAX-Linz and IPAX-2 clinical trials, and have previously shown efficacy in the IPAX-1 trial.
STAT
APRIL 17, 2024
Before the Covid-19 pandemic, viral hepatitis killed more people in the United States than all 60 other reportable infectious diseases combined, including HIV, pneumonia, and tuberculosis. Which doesn’t really make sense, since effective vaccines are available for hepatitis A and B, there are successful therapies for hepatitis B, and there’s a treatment that can cure hepatitis C.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Pharmacy Times
APRIL 17, 2024
IMPACT CKD, a modeling analysis created by AstraZeneca, includes data about chronic kidney disease across 8 countries, including the United States.
Fierce Healthcare
APRIL 17, 2024
Health systems across the country face the same pressing problem — rising levels of burnout among physicians. It’s a challenge that’s reaching a crisis point. | A growing number of hospitals and health systems are betting on advancements in AI as part of the cure for what ails physicians. Rush University System for Health is partnering with Suki to trial its AI assistant and Children’s Hospital Los Angeles is rolling out Nabla's Copilot tool.
STAT
APRIL 17, 2024
At the J.P. Morgan Healthcare Conference in January, Teladoc CEO Jason Gorevic dismissed the growing chorus of naysayers, expressing confidence in his company’s trajectory and asserting, “I think that we are probably still underappreciated with respect to our market advantage, the financial performance that we’ve demonstrated, as well as the bright outlook we have in terms of our growth potential going forward.
pharmaphorum
APRIL 17, 2024
Discover how AI is transforming medical communications and reshaping the future of healthcare. Learn about the latest trends, technologies, and advancements in this rapidly evolving field.
STAT
APRIL 17, 2024
Consumer neurotechnology is booming. You can buy a funky-looking headband for $500 on the internet if you want your own personal EEG to track your brain data. But before you click purchase, you might want to check out the device’s privacy policy. These consumer devices are unlikely to include any protections or restrictions around how companies can employ or sell a user’s neural data, according to a new report from the Neurorights Foundation , a nonprofit that advocates for the eth
pharmaphorum
APRIL 17, 2024
Learn about the importance of reshoring the UK pharmaceutical supply chain for future resilience. Discover how this strategic move can enhance local production and secure the availability of critical medications.
Drug Topics
APRIL 17, 2024
A Q&A with Douglas Hoey, CEO of NCPA, on how the new provision from CMS requiring DIR fees at the point of sale is impacting independent pharmacies in 2024.
pharmaphorum
APRIL 17, 2024
Sage Therapeutics has suffered another disappointment after deciding that it will have to drop the Parkinson’s programme for key pipeline drug dalzanemdor after it showed no benefit in a phase 2 trial. The oral positive allosteric modulator (PAM) of the NMDA receptor is being investigated to see if it can counteract mild cognitive impairment in neurodegenerative disorders, and the PRECEDENT trial in Parkinson’s is the first major readout from the drug programme.
Fierce Pharma
APRIL 17, 2024
In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. | In addition to their acclaimed efficacy against diabetes and obesity, GLP-1 drugs are gaining traction for their potential to treat a variety of other common disorders. Now, two trials have shown that Eli Lilly’s weight loss product Zepbound (tirzepatide) can help patients overcome obstructive sleep apnea (OSA).
pharmaphorum
APRIL 17, 2024
The FTC is seeking a $7 million fine on telehealth company Cerebral for violating patients' data privacy and making cancellation difficult.
STAT
APRIL 17, 2024
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. So the GLP-1s strike again: Eli Lilly’s Zepbound seems to work in obstructive sleep apnea as well. Beyond that, we see up close how Amylyx’s ALS drug — which it is pulling from the market — really didn’t differ much from placebo, and see more market and investment potential for psychedelics.
pharmaphorum
APRIL 17, 2024
As Reuters Pharma Europe 2024 comes to a close in Barcelona, pharmaphorum remains on site to live blog the last remaining talks and insights.
STAT
APRIL 17, 2024
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it this far, and remember there are only a few more days until the weekend arrives. So keep plugging away. After all, what are the alternatives? While you ponder the possibilities, we invite you to join us for a delightful cup of stimulation. Our choice today is maple bourbon.
pharmaphorum
APRIL 17, 2024
MaaT Pharma's microbiota therapy MaaT013 shows survival benefit in acute GvHD in an early access programme, boding well for an ongoing phase 3 trial.
Outsourcing Pharma
APRIL 17, 2024
Pharma companies need to take greater ownership to make sure data quality and governance is accomplished - and it is important to keep in mind the ethics of AI use will remain front and centre for the pharma industry.
pharmaphorum
APRIL 17, 2024
GSK reveals data from EAGLE-1 trial of novel antibiotic gepotidacin for gonorrhoea, amid growing resistance to existing antibiotics.
Fierce Healthcare
APRIL 17, 2024
More than a fifth of the healthcare companies that filed for bankruptcy last year were owned by private equity firms, which also have a hand in many healthcare companies teetering on the brink in 2 | Private equity-backed companies represented more than 20% of last year's healthcare bankruptcies, handily outpacing those of the past five years. Further, nearly all of the companies with high credit risk going into 2024 were owned by private equity firms.
pharmaphorum
APRIL 17, 2024
Drug shortages fuelled by Brexit are now the 'new normal' in the UK and worsened in 2023, says Nuffield Trust report.
Outsourcing Pharma
APRIL 17, 2024
Bormioli Pharma creates pharmaceutical packaging for drug stability, safety, and sustainability, partnering with global health leaders and says it stands at the forefront of sustainability.
Fierce Pharma
APRIL 17, 2024
After proving the merits of its drug delivery platform last year with the approval of Teva’s long-acting schizophrenia drug Uzedy, France’s Medincell has hooked another big-name partner. | Medincell and AbbVie inked a development and licensing pact to create up to six long-acting injectables, Medincell said Wednesday. Under the deal, Medincell is line to receive an upfront payment of $35 million plus much more in potential development and commercial milestones.
Expert insights. Personalized for you.
201 
Let's personalize your content